Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Nexttrip Inc's Business Segments
Nexttrip Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
2
Largest Segment
Travel
Total Revenue
$ 4
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Travel98.2%
- Media1.8%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Travel | $ 1 | 98.2% |
| Media | $ 0 | 1.8% |
Annual Results
Revenue Share by Reportable Segment - FY2026
- Travel99.1%
- Media2.6%
- Corporate0%
Revenue by Reportable Segment - FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Travel | $ 4 | 99.1% |
| Media | $ 0 | 2.6% |
| Corporate | - | 0% |
Description of Nexttrip Inc
The business operations of Neurotrope Inc. revolve around the development and commercialization of therapies for neurodegenerative diseases. Neurotrope is primarily focused on finding treatments for Alzheimer's disease.
Some specific business operations of Neurotrope Inc. include:
1. Research and Development: Neurotrope invests in research and development activities to discover and develop new therapies for Alzheimer's disease. This includes conducting preclinical and clinical trials, exploring potential drug candidates, and optimizing treatment methodologies.
2. Clinical Trials: The company conducts clinical trials to test the safety and efficacy of its drug candidates. These trials involve collaboration with medical centers, hospitals, and research institutions to assess the potential effectiveness of the treatments on patients.
3. Intellectual Property: Neurotrope Inc. files patent applications to protect its research discoveries, drug formulations, and other intellectual property related to its treatment methodologies. This helps the company to secure its innovations and maintain a competitive edge in the market.
4. Regulatory Compliance: The company adheres to regulatory requirements imposed by relevant authorities, such as the U.S. Food and Drug Administration (FDA). Neurotrope ensures that its clinical trials and drug development processes comply with the necessary regulations and guidelines.
5. Commercialization: Once a drug candidate successfully completes the clinical trial phases, Neurotrope focuses on commercialization efforts. This involves seeking approvals from regulatory agencies, negotiating partnerships or licensing agreements with pharmaceutical companies, and preparing the drug for commercial launch.
6. Marketing and Sales: After commercialization, Neurotrope engages in marketing and sales activities to promote its approved therapies to healthcare professionals, hospitals, and patients. This includes developing marketing strategies, attending medical conferences, and establishing distribution networks.
Collaborations and Partnerships: Neurotrope may collaborate with other pharmaceutical companies, research organizations, or academic institutions to advance its drug development programs. These collaborations can enhance the company's resources, expertise, and access to potential funding sources.
8. Post-Market Surveillance: Neurotrope has a responsibility to monitor and report any adverse effects or safety concerns associated with its approved therapies. The company ensures that appropriate systems are in place to capture and evaluate post-market data to maintain drug safety and regulatory compliance.
Some specific business operations of Neurotrope Inc. include:
1. Research and Development: Neurotrope invests in research and development activities to discover and develop new therapies for Alzheimer's disease. This includes conducting preclinical and clinical trials, exploring potential drug candidates, and optimizing treatment methodologies.
2. Clinical Trials: The company conducts clinical trials to test the safety and efficacy of its drug candidates. These trials involve collaboration with medical centers, hospitals, and research institutions to assess the potential effectiveness of the treatments on patients.
3. Intellectual Property: Neurotrope Inc. files patent applications to protect its research discoveries, drug formulations, and other intellectual property related to its treatment methodologies. This helps the company to secure its innovations and maintain a competitive edge in the market.
4. Regulatory Compliance: The company adheres to regulatory requirements imposed by relevant authorities, such as the U.S. Food and Drug Administration (FDA). Neurotrope ensures that its clinical trials and drug development processes comply with the necessary regulations and guidelines.
5. Commercialization: Once a drug candidate successfully completes the clinical trial phases, Neurotrope focuses on commercialization efforts. This involves seeking approvals from regulatory agencies, negotiating partnerships or licensing agreements with pharmaceutical companies, and preparing the drug for commercial launch.
6. Marketing and Sales: After commercialization, Neurotrope engages in marketing and sales activities to promote its approved therapies to healthcare professionals, hospitals, and patients. This includes developing marketing strategies, attending medical conferences, and establishing distribution networks.
Collaborations and Partnerships: Neurotrope may collaborate with other pharmaceutical companies, research organizations, or academic institutions to advance its drug development programs. These collaborations can enhance the company's resources, expertise, and access to potential funding sources.
8. Post-Market Surveillance: Neurotrope has a responsibility to monitor and report any adverse effects or safety concerns associated with its approved therapies. The company ensures that appropriate systems are in place to capture and evaluate post-market data to maintain drug safety and regulatory compliance.
Neurotrope, Inc. is a biotechnology company primarily focused on developing novel therapeutics for neurodegenerative diseases, with a significant emphasis on Alzheimer’s disease. Here’s an extensive overview of the company’s segments, products, and services:
Segments
1. Research and Development (R&D):
- The company invests heavily in R&D to innovate and enhance its therapeutic offerings, targeting underlying biological mechanisms in neurodegenerative conditions. Their R&D efforts are centered on understanding and addressing the pathophysiology of diseases like Alzheimer’s through both preclinical and clinical trial stages.
2. Clinical Trials:
- Neurotrope conducts clinical trials to assess the safety, tolerability, and efficacy of its therapeutic candidates. These trials often involve multiple phases, starting from early-stage trials aimed at safety to larger, pivotal studies needing to generate substantial clinical data supporting potential market approval.
3. Commercialization:
- Once therapies complete clinical development and receive regulatory approval, Neurotrope focuses on developing strategies for bringing these products to market. This segment involves marketing efforts, establishing distribution partnerships, and engaging with healthcare providers to facilitate product adoption.
Products
1. Bryostatin:
- Bryostatin is Neurotrope’s lead product candidate being developed for the treatment of Alzheimer’s disease and other neurodegenerative conditions. The product is a synthesized version of a natural compound derived from the marine bryozoan, Bugula neritina. Bryostatin is believed to have neuroprotective properties that may help promote synaptogenesis and enhance cognitive function in Alzheimer’s patients.
2. Combination Therapies:
- Neurotrope is exploring the possibility of using Bryostatin in conjunction with other therapeutic agents to create combination therapies. This approach aims to enhance treatment efficacy and address multiple aspects of disease pathology by using multiple mechanisms of action.
3. Research Services:
- Neurotrope engages in partnerships with academic institutions and research organizations, providing research services that may involve access to their proprietary technologies, expertise in neurobiology, and methods for assessing drug candidates.
Services
1. Consultation and Advisory Services:
- Neurotrope offers consulting services to assist other biotech firms or research institutions in navigating the development landscape for neurodegenerative therapies. This includes strategic advice on clinical trial design, regulatory pathways, and market entry strategies.
2. Collaborative Research Programs:
- The company may engage in collaborative research programs with universities and pharmaceutical companies to leverage shared expertise and resources, facilitating advancements in drug discovery and development.
3. Regulatory Support:
- Providing insights and support for navigating the regulatory landscape is another service Neurotrope may offer. This is crucial for ensuring that their therapies meet the necessary safety and efficacy standards for market approval.
Innovation and Future Developments
Neurotrope is committed to continuous innovation in the field of neuropharmacology. The development pipeline may include exploring new delivery methods for Bryostatin and identifying additional indications for its therapeutic candidates. Furthermore, the company may look into utilizing emerging technologies such as biomarker development for patient stratification and enhanced therapeutic targeting.
In summary, Neurotrope, Inc. operates at the intersection of innovative R&D, clinical therapeutics, and collaborative partnerships, dedicated to addressing significant unmet needs within neurodegenerative diseases, particularly Alzheimer’s.
Segments
1. Research and Development (R&D):
- The company invests heavily in R&D to innovate and enhance its therapeutic offerings, targeting underlying biological mechanisms in neurodegenerative conditions. Their R&D efforts are centered on understanding and addressing the pathophysiology of diseases like Alzheimer’s through both preclinical and clinical trial stages.
2. Clinical Trials:
- Neurotrope conducts clinical trials to assess the safety, tolerability, and efficacy of its therapeutic candidates. These trials often involve multiple phases, starting from early-stage trials aimed at safety to larger, pivotal studies needing to generate substantial clinical data supporting potential market approval.
3. Commercialization:
- Once therapies complete clinical development and receive regulatory approval, Neurotrope focuses on developing strategies for bringing these products to market. This segment involves marketing efforts, establishing distribution partnerships, and engaging with healthcare providers to facilitate product adoption.
Products
1. Bryostatin:
- Bryostatin is Neurotrope’s lead product candidate being developed for the treatment of Alzheimer’s disease and other neurodegenerative conditions. The product is a synthesized version of a natural compound derived from the marine bryozoan, Bugula neritina. Bryostatin is believed to have neuroprotective properties that may help promote synaptogenesis and enhance cognitive function in Alzheimer’s patients.
2. Combination Therapies:
- Neurotrope is exploring the possibility of using Bryostatin in conjunction with other therapeutic agents to create combination therapies. This approach aims to enhance treatment efficacy and address multiple aspects of disease pathology by using multiple mechanisms of action.
3. Research Services:
- Neurotrope engages in partnerships with academic institutions and research organizations, providing research services that may involve access to their proprietary technologies, expertise in neurobiology, and methods for assessing drug candidates.
Services
1. Consultation and Advisory Services:
- Neurotrope offers consulting services to assist other biotech firms or research institutions in navigating the development landscape for neurodegenerative therapies. This includes strategic advice on clinical trial design, regulatory pathways, and market entry strategies.
2. Collaborative Research Programs:
- The company may engage in collaborative research programs with universities and pharmaceutical companies to leverage shared expertise and resources, facilitating advancements in drug discovery and development.
3. Regulatory Support:
- Providing insights and support for navigating the regulatory landscape is another service Neurotrope may offer. This is crucial for ensuring that their therapies meet the necessary safety and efficacy standards for market approval.
Innovation and Future Developments
Neurotrope is committed to continuous innovation in the field of neuropharmacology. The development pipeline may include exploring new delivery methods for Bryostatin and identifying additional indications for its therapeutic candidates. Furthermore, the company may look into utilizing emerging technologies such as biomarker development for patient stratification and enhanced therapeutic targeting.
In summary, Neurotrope, Inc. operates at the intersection of innovative R&D, clinical therapeutics, and collaborative partnerships, dedicated to addressing significant unmet needs within neurodegenerative diseases, particularly Alzheimer’s.